Introduction
Transcatheter aortic valve replacement (TAVR) is rapidly gaining importance as a safe and feasible alternative to surgical aortic valve replacement (SAVR) for patients with symptomatic severe aortic stenosis. 1 Despite the advances TAVR offers, post-procedural assessment of valve function remains challenging. 2 Echocardiography remains the gold standard imaging modality in assessment of prosthetic function of transcatheter implanted valve prosthesis, but the lack of familiarity with the normal and pathological flow properties of the new valve prosthesis leaves uncertainty for classification of valvular function. 3 Overall the basic principles used for evaluation of SAVR can be applied, but with some important particularities and caveats specific to TAVR. 3, 4 Similar to native valves, pressure gradients, transvalvular velocities, and effective orifice areas are quantified, but should be interpreted cautiously with regard to the implanted valve type. Unlike native valve, the artificial nature of prosthetic valves always inheres obstructive elements, reflected by increased pressure gradients and transvalvular velocities, which makes the differentiation between normal valve performance and prosthetic valve dysfunction challenging. surgical stented bioprosthesis. 6 Nevertheless, the stent structure per se interferes with the calculation of the effective orifice area or other indices of valve opening. As these indices are based on the ratio of post-to pre-valvular velocities, the flow acceleration within the stent proximal and at the level of the cusps may result in an overestimation of the valve area. 7, 8 Furthermore, special attention has been recently paid to valve leaflet motion, as reduced leaflet mobility has been related to subclinical leaflet thrombosis with the subsequent high risk for transient ischaemic attacks. 9 This phenomenon seems to be more frequent in TAVR as compared with SAVR with incidence rates of up to 13% of the TAVR patients. In clinical practice, a high aortic valve gradient > _20 mmHg or an increase of 10 mmHg should raise concerns regarding the presence of valvular thrombosis, but the vast majority (85%) presents haemodynamically silent with normal valve gradients. 10 Taken together, the comprehensive interpretation of the echocardiographic data requires knowledge on type and size of the valve as well as in-depth knowledge on the mechanical properties of the respective valve. The rapidly growing number of available TAVR prosthesis urges the need for a comprehensive summary on normal values of the different TAVR types that guide clinicians to judge if the individual patient has a TAVR-type specific normal prosthetic valve function. The aim of the present study was to collect and pool all the available echocardiographic data from all currently available TAVR prosthesis published in literature in order to provide a comprehensive overview of normal values for these prostheses.
Methods
The reported search strategy, study selection, data extraction, and analysis were performed according to the PRISMA guidelines for systematic reviews and meta-analyses.
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Search strategy were additionally screened for on-going and completed trials. The search strategy was based on the combination of disease, therapy, and study design using 'AND' and 'OR'. The following search terms were combined as keywords or MeSH terms: 'aortic valve stenosis' or 'aortic valve disease' with 'transcatheter' or 'transfemoral' or 'transapical' or 'TAVR' or 'TAVI'. The search was limited to prospectively collected data in adults published in English.
Study selection and data extraction
All published studies investigating TAVR were identified. M.W and P.S screened titles and/or abstracts for inclusion and in a second step all potentially suitable articles were reviewed for final eligibility. Duplicates were identified using the reference management software EndNote X6 (Thomson Reuters, NY, USA) and excluded. Additionally, the bibliographies of all included articles were reviewed to identify further relevant studies. Only prospective trials and registries were included. Full-texts of all includable trials were obtained and three investigators (M.W., A.K., and M.Z.) independently assessed study eligibility and extracted the relevant data. The following details were recorded for each study: first author, title, PubMed Identifier (PMID), study design, patient characteristics, inclusion criteria, valve type and delivery route, echocardiographic data, and funding.
Definitions and interventions
Studies were only eligible if participants were prospectively included and if the studies reported echocardiographic measurements for normal TAVR valves specifying valve type and time point of assessment. Studies investigating rare aetiologies of aortic valve disease (valve thrombosis, bicuspid valves) or other indications than conventional TAVR (valvein-valve procedure, bail-out procedures, non-aortic position) were excluded. Studies investigating more than one valve type were only included if there was a separate analysis of every valve type available. In studies reporting different delivery routes (transapical vs. transarterial) or different valve sizes separately, echocardiographic data were pooled and the mean value and the standard deviation (SD) of the pooled data were calculated.
Outcomes and measurements
The primary parameters were peak velocity, peak gradient, mean gradient, and effective orifice area obtained at discharge, 30 days, 3 months, 6 months, and 1 year.
Study quality assessment
Quality of included studies was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions 5. 
Data analysis
Data were pooled if more than one study reported haemodynamic data for a given valve type or size and time point. The means and SD of peak velocity, peak gradient, mean gradient, and effective orifice were computed as described previously. 5 Before pooling, extracted data were transformed from standard error of the mean or confidence interval to SD. Statistical analysis was performed using the programme Review 
Results
The pre-defined electronic search strategy on PUBMED, SCOPUS, Cochrane Central Register of Controlled Trials, and LILAC retrieved 11 889 citations that were initially evaluated for eligibility upon title and abstract level ( Figure 1 ). After exclusion of duplicates and irrelevant publications, 155 articles reporting echocardiographic measurements of TAVR prosthesis in 27 159 patients were included and are itemized in detail in our Supplementary data online, References 21-175. Of these, 149 studies reported 2D transthoracic echocardiographic measurements, and six studies used transoesophageal 2D echocardiography. Inter-readers agreement was high (Kappa coefficient 0.99). In total, 35 875 measurements at four time-points were analysed with 138 studies (89%) reporting echocardiographic data post-procedure or at discharge, 65 studies (42%) stated 30-day postprocedural measurements, only 4 studies (2%) studied patients 3-month post-procedure, 16 (17%), and 37 (24%) studies report data 6-month or 1-year post-procedural, respectively. The data for all Figure 3 ). In all investigated prosthesis types, we observed a mild increase in the different Doppler indices from the discharge to the long term follow up (Figures 2 and 3) . However, the changes were minor reassuring the stable haemodynamic performance of the different TAVR prosthesis up to 1 year after implantation. Furthermore, we aimed to investigate if the refined second and third generation successors of the available major TAVR prosthesis show superior haemodynamic characteristics as compared with the first generation devices. We found no significant difference in mean transprosthetic gradient at discharge between the Edwards Sapien and the Edwards Sapien XT (9.85 ± 4.19 mmHg vs. 9.94± 4.7 mmHg, P ¼ 0.40). Interestingly, the analysis revealed a significant higher mean gradient of the Edwards Sapien III valve as compared with the Edwards Sapien (10.45 ± 4.91 vs. 9.85 ± 4.19 mmHg, P < 0.001), and the Edwards Sapien XT (10.45 ± 4.91 vs. 9.94± 4.7 mmHg, P < 0.001). In contrast to this, the newer Medtronic Evolut TM R showed significant lower mean gradients at baseline as compared with its predecessor model Medtronic CoreValveV R (7.41± 4.7 vs. 8.53± 4.7, P < 0.001).
Discussion
In the present study, we provide the first comprehensive overview on normal values for Doppler gradients, transvalvular velocities, and effective orifice areas for available transcatheter valve systems approved in human use, extracted and pooled from the currently available literature. All studies included, where either prospective observational studies or national-and device-specific registries or randomized clinical trials. The primary idea of this analysis was to provide robust echocardiographic data that should help physicians during clinical follow-up, as the post-procedural assessment of valve function still remains challenging. 2 Indisputable echocardiography is the key imaging modality for assessing prosthetic function of transcatheter implanted valve prosthesis, but major differences and limitations specific to TAVR should be considered. 13 Doppler echocardiography that is utilized for haemodynamic assessment relies on flow-dependent (peak aortic velocity, mean TAV gradients) and flow-independent parameters (effective orifice area, Doppler velocity index). In TAVR prosthesis, flow dependent variables are generally higher, because as in contrast to a native valve, prosthetic valves always inheres an obstructive element, reflected by increased pressure gradients and increased transvalvular velocities. 3, 4 All available TAVR types are stented bioprostheses that have been reported to be even more obstructive to the natural flow. 6, 14 In this context, establishing a 'normal range' is challenging For this purpose, it might be helpful to interpret transvalvular gradients with regard to the measured effective orifice area (EOA). 13 Consequently the Valve Academic Research Consortium-2 (VARC-2) advocates using this integrative approach and propose the initial haemodynamic evaluation by using one flow dependent (e.g. mean gradient) and one flow independent criterion (e.g. EOA) for the initial haemodynamic evaluation. 15 Although not completely independent and altered by flow acceleration within the stent proximal and at the level of the cusps, EOA is particularly useful to assess the functional status of the valve. 7, 8 Special attention should be paid to the visual appearance of the bioprosthesis, as some signs of a dysfunctional TAV may be present before increased Doppler indexes. 3 Systematic evaluation of computed tomography scanning's revealed increased cusp thickness and reduced leaflet mobility to be related to subclinical leaflet thrombosis with the subsequent high risk for transient ischaemic attacks. 9 Reported incidence rates of up to 13% in TAVR patients substantially exceed the frequency observed in SAVR. Although 85% of those patients present haemodynamically silent with normal valve gradients, high aortic valve mean gradient > _ 20 mmHg or an increase of 10 mmHg should raise concerns regarding the presence of valvular thrombosis.
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Indeed due to the non-invasive nature and the wide availability, transthoracic echocardiography is also the key diagnostic tool in evaluation of TAVR prosthesis thrombosis and its limited sensitivity might be improved by the valve specific reference values presented in this analysis. In this context, the use of additive imaging methods like transoesophageal 3D echocardiography or computed tomography might be highly beneficial.
In the present analysis, we observed a numerical trend towards an increase of trans-prosthetic gradients from discharge to 1 year of follow-up. However, this increase was only minimal, demonstrating a stable haemodynamic performance up to 1 year after implantation. Additionally, this mild increase may not only be a sequel prosthetic valve dysfunction but also be induced by recovery of left ventricular ejection fraction (LVEF) after TAVR. Unfortunately, the majority of the included studies did not report data on LVEF recovery and the role of this phenomenon cannot be elucidated with the present review. Furthermore, we observed mildly increased Doppler indices at discharge of the second and third generation successors as compared with the first generation devices. Although these differences were minimal and presumably clinically not relevant, this observation may suggest that the refinements of these valves to reduce paravalvular regurgitation come at the dispense of increased Doppler gradients. Taken together, the comprehensive evaluation of the obtained Doppler echocardiographic data requires the knowledge on type and size of the implanted valve and should be interpreted under synopsis of the baseline values for each valve, as every valve inheres a specific haemodynamic fingerprint. 16 Although valuable, the in-depth knowledge on the mechanical properties of the every valve is in times of rapidly growing number of available TAVR prosthesis not feasible. For this purpose, we propose to use the presented tables that provide an overview on the currently available data of normal values to facilitate adequate interpretation of Doppler data.
Limitations
In the present study, echocardiographic data for the estimation of normal values were pooled from a large group of patients with assumed normal TAVR prosthetic valve function. The so calculated normal values indicate, that patients presenting with values exceeding these ranges are very likely to have valve dysfunction. Nevertheless as only patients with normal function were included in these studies and our analysis, it is uncertain how frequently prosthetic dysfunction occurs in patients with values below our calculated cut-offs. In clinical practice, these cut-offs might provide a reasonable specificity for identification of patients with prosthetic dysfunction that might benefit from further additional imaging modalities such as Multiple detector computed tomography (MD-CT) but sensitivity remains unclear. All presented echocardiographic variables may be influenced by the implanted prosthesis size. 17 Unfortunately, only a minority of the included studies presented the echocardiographic measurements according to the implanted prosthesis size ( Table 3) . As velocities and gradients are dependent on flow, these data should be interpreted in consideration of the flow situation and therefore normal values should be given for specific flow rates. Unfortunately those are generally not available. 5 However the included studies did not report to have included measurements obtained from time points of instable haemodynamic conditions and therefore the reported variables most likely resemble those measurements obtained during routine echocardiographic follow-up. In the present analysis, we observed a mild increase of trans-prosthetic gradients from discharge to 1 year of follow-up. This increase may not only be a sequel prosthetic valve dysfunction but also be induced by recovery of LVEF after TAVR. Unfortunately, the majority of the included studies did not report data on LVEF recovery and the role of this phenomenon cannot be elucidated with the present review. We aimed to include all trials that reported echocardiographic data for TAVR prosthesis. However, landmark trials like SURTAVI, 18 PARTNER II, 19 and the U.S. CoreValve High Risk Study (PIVOTAL trial) 20 illustrated their echocardiographic data as figure but did not report specific values which made inclusion in our analysis not feasible.
Conclusion
The present study firstly describes a pooled analysis of normal values in a total of 27 159 patients for all available TAVR prosthesis classified according to implanted valve size and time since implantation. The presented data empower the treating physician with a comprehensive tool to perform follow-up echocardiographic assessment in TAVR patients and to safely identify patients with possible prostheses dysfunction.
